Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
1. A cell-binding agent-cytotoxic agent conjugate represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
CB is a cell-binding agent, wherein the cell-binding agent is an antibody or an antigen binding fragment thereof;
L 2 represented by the following formula:
wherein:
R x and R y are both H;
l and l1 are each an integer from 2 to 6; and
k1 is an integer from 1 to 5;
s1 indicates the site that is connected to the cell-binding agent CB and s3 indicates the site that is connected to the group A;
A is an amino acid residue or a peptide comprising 2 to 20 amino acid residues;
R 1 and R 2 are each independently H or a C 1-3 alkyl;
L 1 is —L 1′ —C(═O)—, wherein L 1′ is an alkylene or a cycloalkylene; and wherein the —C(═O)— moiety in L 1 is connected to D;
q is an integer from 1 to 20; and D is represented by the following formula:
2. The conjugate of claim 1 , wherein one of R 1 and R 2 is H, and the other one is Me; or R 1 and R 2 are both H.
3. The conjugate of claim 1 , wherein L 1 is —CR 3 R 4 —(CH 2 ) 1-8 —C(═O)—; R 3 and R 4 are each independently H or Me.
4. The conjugate of claim 3 , wherein R 3 and R 4 are both Me.
5. The conjugate of claim 1 , wherein L 1 is —(CH 2 ) 4-6 —C(═O)—.
6. The conjugate of claim 1 , wherein A is a peptide cleavable by a protease expressed in tumor tissue.
7. The conjugate of claim 6 , wherein A is a peptide having an amino acid that is covalent linked with —NH—CR 1 R 2 —S—L 1 —D selected from the group consisting of Ala, Arg, Asn, Asp, Cit, Cys, selino-Cys, Gln, Glu, Gly, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val, each independently as L or D isomer.
8. The conjugate of claim 7 , wherein the amino acid connected to —NH—CR 1 R 2 —S—L 1 —D is an L amino acid.
9. The conjugate of claim 1 , wherein A is selected from the group consisting of Gly-Gly-Gly, Ala-Val, Val-Ala, D-Val-Ala, Val-Cit, D-Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Ala, Phe-N 9 -tosyl-Arg, Phe-N 9 -nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Ala-Ala, D-Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala-D-Ala, Ala-Leu-Ala-Leu (SEQ ID NO: 1), β-Ala-Leu-Ala-Leu (SEQ ID NO: 2), Gly-Phe-Leu-Gly (SEQ ID NO: 3), Val-Arg, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Gln-Val, Asn-Ala, Gln-Phe, Gln-Ala, D-Ala-Pro, and D-Ala-tBu-Gly, wherein the first amino acid in each peptide is connected to L 2 group and the last amino acid in each peptide is connected to —NH—CR 1 R 2 —S—L 1 —D.
10. The conjugate of claim 9 , wherein D is represented by the following formula:
11. The conjugate of claim 1 , wherein the conjugate is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
is the cell-binding agent connected to the L 2 group through a Cys thiol group;
R 3 and R 4 are each independently H or Me;
r1 and t1 are each independently an integer from 1 to 6;
r2 and t2 are each independently an integer from 1 to 7;
t3 is an integer from 1 to 12;
D 1 is represented by the following formula:
12. The conjugate of claim 11 , wherein A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly; r1 is independently an integer from 2 to 4; and r2 is independently an integer from 3 to 5.
13. The conjugate of claim 11 , wherein the conjugate is represented by the following formula:
wherein:
r1 and t1 are each an integer from 2 to 6;
r2 and t2 are each an integer from 2 to 5; and
t3 is an integer from 2 to 12.
14. The conjugate of claim 13 , wherein R 3 and R 4 are both Me.
15. The conjugate of claim 13 , wherein R 3 and R 4 are both H.
16. The conjugate of claim 11 , wherein the conjugate is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly, and
D 1 is represented by the following formula:
17. The conjugate of claim 16 , wherein the conjugate is represented by the following formula:
wherein D 1 is represented by the following formula:
18. The conjugate of claim 1 , wherein, the cell-binding agent is a humanized antibody or a humanized antibody fragment thereof, a single chain antibody, a single chain antibody fragment that specifically binds to a target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to a target cell, a domain antibody, or a domain antibody fragment that specifically binds to a target cell.
19. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.
20. The conjugate of claim 17 , wherein the conjugate is represented by the following formula:
21. The conjugate of claim 17 , wherein the conjugate is represented by the following formula: